Indeed, our time-matched immunohistochemistry (IHC) and Western blot analysis of 005GSC implanted mouse GBM tissues showed that αPD1 treatment led to elevated Wnt7b and β-catenin (nuclear and perinuclear) levels (Fig. 2 A–D and SI Appendix, Fig. S5A). The gene discussed is WNT7B; the disease is glioblastoma.